PDCD1 and neoplasm: The combination of monalizumab, a humanized anti-NKG2A antibody, with a PD-1-PD-L1 axis blocker enhances NK cell activity against a variety of tumor cells and rescues CD8+ T-cell function, a novel mechanism of checkpoint inhibition.